Celemics, Inc. (KOSDAQ: 331920)

Market Cap	26.45B
Revenue (ttm)	6.01B
Net Income (ttm)	21.91B
Shares Out	8.16M
EPS (ttm)	2,683.82
PE Ratio	1.21
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,400
Open	3,445.00
Previous Close	3,480.00
Day's Range	3,270.00 - 3,465.00
52-Week Range	2,805.00 - 10,400.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 18, 2025

About Celemics

Celemics, Inc. designs, manufactures, and distributes sequencing kits in South Korea. The company offers whole exome sequencing panels; NGS target enrichment panels; customized and ready-to-use enrichment panels; and modular accessories, including library preparation kits, double standard Cdna synthesis, hybridization enhancer, celan-up and streptavidin beads, CeleNM beads, and polymerase. It also provides celemics analysis, whole exome sequencing, customized NGS panels, sequencing, bioinformatics, biopharma, and custom NGS assay development se...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2010
• Employees: 42
• Stock Exchange: KOSDAQ
• Ticker Symbol: 331920

Financial Performance

In 2023, Celemics's revenue was 6.58 billion, a decrease of -24.65% compared to the previous year's 8.73 billion. Losses were -3.88 billion, -19.21% less than in 2022.